Hemolytic uremic syndrome (HUS)

Definition and Overview

• Hemolytic uremic syndrome (HUS) is a primary cause of community-acquired acute kidney injury (AKI) in children and represents the most common form of thrombotic microangiopathy (TMA) in the pediatric population.
• The condition is classically defined by a clinical triad comprising microangiopathic hemolytic anemia (MAHA), consumptive thrombocytopenia, and acute kidney injury.
• While the final clinical manifestation of TMA is uniform across different etiologies, the underlying pathophysiology varies significantly, heavily influencing specific management strategies.

Classification of Hemolytic Uremic Syndrome

Pathogenesis and Pathophysiology

Shiga Toxin-Associated HUS (STEC-HUS)

• STEC-HUS typically follows ingestion of contaminated food or water, leading to localized intestinal infection and hemorrhagic enterocolitis.
• The enteropathogenic organisms release Shiga toxins (Stx1 and Stx2), which are absorbed from the colonic mucosa into the systemic circulation.
• Shiga toxins possess a high affinity for globotriaosylceramide (Gb3) receptors, which are abundantly expressed on the surface of human renal microvascular endothelial cells, podocytes, and tubular epithelial cells.
• Upon binding, the toxin is internalized and halts cellular protein synthesis by inactivating ribosomes, resulting in direct endothelial cell death and apoptosis.
• This localized endothelial injury provokes a highly pro-thrombotic state characterized by fibrin deposition and the formation of platelet microthrombi within the glomerular capillaries and afferent arterioles.
• Polymorphonuclear neutrophils (PMNs) are also actively involved, migrating to the site of injury, releasing proteolytic enzymes, and generating reactive oxygen species, thereby exacerbating the inflammatory endothelial damage.

Pneumococcal-Associated HUS (P-HUS)

• The pathogenesis of P-HUS centers on the bacterial production of the neuraminidase enzyme during an invasive pneumococcal infection.
• Neuraminidase cleaves terminal sialic acid residues from the surface glycoproteins of host red blood cells (RBCs), platelets, and renal endothelial cells.
• This cleavage exposes the normally hidden Thomsen-Friedenreich (T) antigen.
• Pre-existing, circulating endogenous host IgM antibodies recognize and bind to the newly exposed T antigen, triggering a massive immune and complement-mediated attack on these cells, precipitating hemolysis and widespread microvascular thrombosis.

Atypical HUS (aHUS)

• aHUS is driven by a fundamental defect in the regulation of the alternative complement pathway, resulting in unremitting complement activation directly on the surface of the host's vascular endothelium.
• The condition is caused by loss-of-function mutations in complement regulatory genes (e.g., CFH, CFI, MCP/CD46) or gain-of-function mutations in effector genes (e.g., C3, CFB).
• Complement Factor H (CFH) mutations are the most frequently identified genetic anomaly.
• In developing nations like India, acquired autoantibodies against Factor H (anti-FH) account for approximately 50% of pediatric aHUS cases, typically presenting between 5 and 15 years of age.
• A specific genetic hallmark of anti-FH aHUS is a homozygous deletion of the CFHR1 gene, which is proposed to predispose individuals to autoantibody formation.

Mechanism of the Clinical Triad

• Acute Kidney Injury: Capillary and arteriolar endothelial injury leads to localized luminal narrowing and thrombosis, which drastically reduces renal blood flow and glomerular filtration rate.
• Thrombocytopenia: Extensive formation of microthrombi results in the massive peripheral consumption and sequestration of circulating platelets.
• Microangiopathic Hemolytic Anemia (MAHA): As red blood cells are forced through the partially occluded, fibrin-laden microvasculature under high shear stress, they are mechanically sheared and fragmented into schistocytes, leading to non-immune hemolysis.

Clinical Features

Renal and Hematological Manifestations

• STEC-HUS presents 5 to 7 days following a prodrome of abdominal cramps, vomiting, and diarrhea, which becomes bloody in 60-90% of cases.
• The onset of the acute TMA phase is marked by sudden pallor, profound weakness, lethargy, and the emergence of oliguria or anuria.
• Hypertension is prevalent and is typically volume-dependent due to acute oliguric renal failure.
• Depending on fluid management during the prodromal phase, patients may present with severe hypovolemic dehydration or significant volume overload leading to pulmonary edema.
• Macroscopic hematuria is transient if present, but microscopic hematuria and low-grade to nephrotic-range proteinuria are practically universal.
• The condition may present as a rapidly progressive illness, with up to 50–60% of pediatric patients requiring acute renal replacement therapy (dialysis).

Extra-renal Manifestations

Diagnostic Evaluation

Core Laboratory Findings

• Hematology: Hemoglobin typically falls below 10 g/dL. The peripheral blood smear is diagnostic, demonstrating >2% fragmented red cells (schistocytes, helmet cells, burr cells) alongside a robust reticulocytosis.
• Platelets: Consumptive thrombocytopenia is invariable during the acute phase, with platelet counts characteristically dropping below 150,000/μL, often ranging between 20,000 and 100,000/μL.
• Hemolysis Markers: Serum lactate dehydrogenase (LDH) is markedly elevated (>450 IU/L), indirect bilirubin is increased, and serum haptoglobin is profoundly reduced or undetectable due to rapid binding of free hemoglobin.
• Renal Function: Blood urea nitrogen (BUN) and serum creatinine are elevated in proportion to the degree of acute kidney injury. Hyponatremia, hyperkalemia, and metabolic acidosis are frequent severe complications of the oliguric state.
• Coombs Test: The direct erythrocyte antiglobulin (Coombs) test is characteristically negative in STEC-HUS and aHUS, but is distinctively positive in >60% of cases of Pneumococcal HUS.

Differentiating HUS from other TMAs

• Disseminated Intravascular Coagulation (DIC): Unlike DIC, which presents with prolonged prothrombin time (PT), prolonged activated partial thromboplastin time (aPTT), and low fibrinogen, the coagulation profile in HUS is generally normal.
• Thrombotic Thrombocytopenic Purpura (TTP): TTP is distinguished by a severe deficiency of ADAMTS13 activity (<10%); assessing ADAMTS13 is indicated if HUS presents with very severe thrombocytopenia (<30,000/μL), minimal renal involvement, or if the etiology remains obscure.

Etiological Workup

Management Strategies

Supportive Care for All HUS Patients

• Meticulous supportive care remains the cornerstone of management and heavily influences survival; therapy is directed at controlling volume status, electrolyte derangements, and mitigating AKI complications.
• Fluid Management: In patients presenting with the dysenteric prodrome, proactive, early intravascular volume expansion with isotonic fluids serves a nephroprotective role, mitigating the risk of progression to severe oliguric AKI. Once anuric AKI is established, strict fluid restriction is paramount to prevent life-threatening pulmonary edema.
• Transfusion Practices: Severe anemia warrants cautious packed red blood cell transfusions. In cases of Pneumococcal HUS, transfused RBCs must be washed to remove residual plasma containing donor antibodies that could cross-react with exposed T-antigens and exacerbate hemolysis.
• Platelet Transfusions: Platelet transfusions are strictly contraindicated as they provide additional substrate for microvascular thrombosis, potentially worsening ischemia; they are reserved solely for clinically significant, life-threatening hemorrhage or prior to invasive surgical procedures.
• Renal Replacement: Early initiation of hemodialysis, continuous renal replacement therapy (CRRT), or peritoneal dialysis is strongly indicated for severe oliguria, anuria, refractory hyperkalemia, or uncontrollable fluid overload.

Management of Shiga Toxin-Associated HUS

• The use of antimicrobial therapy for STEC-induced hemorrhagic colitis is contraindicated in pediatric patients. Antibiotics may induce bacterial lysis and upregulate stx gene expression, prompting a massive release of Shiga toxin that worsens the HUS clinical course.
• Antimotility agents (e.g., loperamide) are actively discouraged as they prolong the retention of toxin-producing bacteria within the gut lumen, facilitating greater systemic toxin absorption.
• There is no evidence supporting the use of plasma exchange, anticoagulants, or systemic fibrinolytics for typical STEC-HUS, as they increase bleeding risks without altering the disease pathophysiology.

Specific Therapy for Atypical HUS (aHUS)

• Plasma Exchange (PEX): In environments where eculizumab is unavailable, prompt initiation of high-volume PEX within 24 hours of diagnosis is the primary intervention. PEX removes circulating mutant complement factors and pathogenic autoantibodies while replacing them with functional regulatory proteins from fresh frozen plasma.
• Terminal Complement Blockade (Eculizumab): Eculizumab, a humanized monoclonal antibody against complement protein C5, acts by blocking the formation of the membrane attack complex (C5b-9). It is the definitive standard of care for genetic aHUS, demonstrating superior capacity to arrest TMA, induce hematological remission, and rescue renal function compared to PEX.
• Management of Anti-Factor H HUS: For this acquired autoimmune form, aggressive PEX is combined with induction immunosuppression (utilizing oral corticosteroids alongside intravenous cyclophosphamide, rituximab, or mycophenolate mofetil). This dual approach achieves rapid clearance of the circulating autoantibodies while suppressing their subsequent production.
• Patients with anti-FH HUS require long-term maintenance immunosuppression and strict monitoring of anti-FH titers, as high antibody levels closely predict disease relapse.
• Kidney transplantation in genetic aHUS carries a high recurrence risk (up to 80-90% for CFH mutations). Prophylactic administration of eculizumab is mandatory in high-risk patients peri- and post-transplantation to prevent rapid allograft loss due to recurrent TMA.

Specific Therapy for Cobalamin C Deficiency

• Prompt recognition is vital, as this entity does not respond to plasma exchange or complement blockade.
• Treatment mandates aggressive metabolic control utilizing parenteral hydroxycobalamin, high-dose oral betaine, and folic acid. This triad bypasses the metabolic block, lowers toxic homocysteine levels, and facilitates neurological and renal recovery.

Prognosis and Complications

• With advanced intensive care and pediatric dialysis, acute mortality in STEC-HUS has fallen below 5%, with most fatalities attributed to severe CNS microvascular thrombosis or ischemic cardiomyopathy.
• Following the acute phase of STEC-HUS, approximately 70% of children achieve full renal recovery.
• However, up to 30% of STEC-HUS survivors sustain permanent renal sequelae, manifesting years later as hypertension, persistent proteinuria, and progressive chronic kidney disease (CKD), necessitating meticulous long-term nephrological follow-up.
• The prognosis for aHUS remains remarkably guarded if untreated or treated solely with plasma therapy; up to 50% of patients progress to end-stage kidney disease (ESKD) or die within 5 years due to relapsing microvascular damage.
• The integration of eculizumab has fundamentally transformed the trajectory of aHUS, dramatically reducing the progression to ESKD to under 15% and permitting successful renal transplantation.